Download presentation
Presentation is loading. Please wait.
1
Tailored GCP & Trial Specific training
FLO-ELA Tailored GCP Training v1.0 10/10/2017
2
What is Good Clinical Practice?
Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of human subjects
3
GCP Training The aim of this session is to provide a basic understanding to perform trial-specific tasks and is not a full GCP course It is based on key slides from the National Institute of Health Research (NIHR) Good Clinical Practice (GCP) slide set This is not valid training for any other study or trial and is not interchangeable
4
Is this the right level of GCP training for you?
No GCP training needed if: Aware of the trial and highlighting potential participants to GCP-trained team (e.g. Research nurse) Tailored GCP training needed if: Delivering the study intervention / control group care Making a first approach to patients to describe the trial and give a PIS (But NOT taking consent) Entering patients into the randomisation system No training needed if: Being aware of the trial and highlighting potential participants to GCP-trained team (e.g. Research nurse) Tailored GCP: Delivering the study intervention / control group care Making a first approach to patients to describe the trial and give a PIS (but NOT taking consent) Entering patients into the randomisation system Full GCP: Assessing eligibility, taking consent (from patient or via consultee agreement / emergency consent) Trial-related decisions e.g. Judging that an event is a Serious Adverse Event Full GCP training needed if: Assessing eligibility, taking consent (from patient or via consultee agreement / emergency consent) Trial-related decisions e.g. Judging that an event is a Serious Adverse Event
5
Objectives Understand there is a set of interwoven laws, guidelines and frameworks which govern the set up and conduct of clinical research Understand basic principles of GCP Outline roles and responsibilities of different individuals within the research
6
Why do we need GCP? Each individual involved in conducting a trial should be qualified by education, training and experience to perform his or her respective task(s) If you are either giving the study treatment, signing off participants as medically stable or prescribing study treatment, you need to know how GCP applies to those tasks The ICH Guideline for Good Clinical Practice says:
7
GCP Principles These form the basis of the guidance and legislation which governs conduct of clinical research carried out in the NHS Important GCP principles (14 total): The rights, safety and well-being of the trial subjects shall prevail over the interests of science and society The necessary procedures to secure the quality of every aspect of the trial shall be complied with All clinical information shall be recorded, handled and stored in such a way that it can be accurately reported, interpreted and verified, while the confidentiality of records of the trial subjects remains protected
8
What are your overall responsibilities?
Fulfil the duties delegated to you Ensure the safety and wellbeing of subjects
9
Patient Consent There is no pressure to participate and if a patient decides not to take part, their existing treatment will not be compromised That consent can be withdrawn at any time without impacting on their care Information given to participants/ consultees must be clear and understandable Participants/ consultees must be given time to consider and to ask questions Local trial team should be satisfied that suitable consent has been sought before undertaking any task You will not be expected to consent patients for this trial but it is important to be aware of the consent procedures.
10
Safety Reporting Data will be gathered in order to monitor the effects of the trial and any interventions on the participants Regular reviews of data safeguard participant safety by highlighting any trends or unexpected events Safety reporting is important in order to protect patients during the trial and once a practice or treatment becomes standard care Notify the research team about any safety events suspected to be related to the trial Notify the research team about any safety events suspected to be related to the trial - These are not just any expected complications after emergency laparotomy but events that are directly related to the specific interventions associated with the trial. the research team will then document on a form and report to the central trial team if required
11
Data Capture A clinical trial is only as good as the quality of the data collected Inaccurate/incomplete data can prevent trial aims and objectives being met and impact on participant safety
12
Standards for data capture
Make sure your writing is legible Always write in black Put a single line through any mistake Make the amendment clear next to it Initial and date any alteration Never occlude the original entry Never use TIPPEX or POST-IT notes E.G On anaesthetic/ITU records – ensure it is clear that (1) patient is in the FLO-ELA trial (2) type of COM used [intervention patients only] (3) mark when a fluid bolus is given (4) record enough detail for the total volumes and types of fluids to be calculated
13
If it is not documented, it did not happen!
Useful Tips Sign/initial and date anything you write or amend If something doesn’t seem right, check If you don’t know ask, because someone will ask you Remember If it is not documented, it did not happen!
14
Trial Specific Training
Trial Design Inclusion/ Exclusion Criteria Patient Consent Pathway Intervention vs. Usual care Non Compliance
15
Trial Design Pragmatic multicentre open randomised trial, supported by data from the ongoing National Emergency Laparotomy Audit (NELA) Sample size = 7646 patients (3823 per arm) Emergency surgery only 100 UK Sites 3 Year Recruitment Internal Feasibility Phase
16
Inclusion Criteria Age ≥50 years
Scheduled to undergo a surgical procedure which fulfils the criteria for entry into the National Emergency Laparotomy Audit (NELA) i.e. an expedited, urgent or emergency abdominal procedure on the gastrointestinal tract within the audit scope Patient has NHS number
17
Exclusion Criteria Inability or refusal to provide patient consent
Clinician refusal Previous enrolment in the FLO-ELA trial Previous inclusion in NELA within the current hospital admission Scheduled abdominal procedure outside the scope of NELA Current participation in another clinical trial of a treatment with a similar biological mechanism During the course of the trial the NELA Project Team may make minor modifications to the definitions of surgical cases included within the audit. In this circumstance the inclusion/exclusion criteria for FLO-ELA will be amended to ensure consistency with NELA.
18
Consent Flowchart
19
Randomisation On day of surgery Via the FLO-ELA randomisation system
As close as possible to the start of anaesthesia, typically when the patient arrives in the theatre suite for surgery Via the FLO-ELA randomisation system Enter patient demographics Confirm eligibility criteria met FLO-ELA Patient ID generated Treatment allocation provided
20
Recommended care for all patients
The intervention should begin immediately following induction of anaesthesia and continue at least until the end of surgery. Patients receiving level 2/3 care should have the intervention continued for 6 hours postop. If a patient is already sedated and ventilated before arrival for laparotomy, the intervention start time is counted as the time of their arrival in the theatre/anaesthetic room. Cardiac output and stroke volume will be measured by one of the three recommended models of cardiac output monitors and algorithm should be followed. It is important to note that if monitoring has been used for less than 80% of the intervention period this meets the definition of non-compliance and should be reported as such.
21
Intervention Group Please refer to the intervention group SOP
Commence at start of general anaesthesia FLO-ELA treatment algorithm – see next slide Stroke volume and stroke volume variation (SVV) will be measured by cardiac output monitor Clinicians may choose from a range of cardiac output monitors in established use Continues at least until the end of surgery; patients receiving level 2/3 critical care after surgery, the intervention will continue for six hours after the end of surgery The intervention should begin immediately following induction of anaesthesia and continue at least until the end of surgery. Patients receiving level 2/3 care should have the intervention continued for 6 hours postop. If a patient is already sedated and ventilated before arrival for laparotomy, the intervention start time is counted as the time of their arrival in the theatre/anaesthetic room. Cardiac output and stroke volume will be measured by one of the three recommended models of cardiac output monitors and algorithm should be followed. It is important to note that if monitoring has been used for less than 80% of the intervention period this meets the definition of non-compliance and should be reported as such.
22
Intervention Algorithm
Handout – laminate Haemodynamic algorithm.
23
Intervention Flowchart
This is the intervention flowchart.
24
Usual Care Group Please refer to control group SOP
Managed by clinical staff according to usual practice Broad criteria to emphasise good care Avoids practice misalignment No cardiac output monitoring unless required to inform treatment of critically ill patient Patients should not be randomised if the clinician intends to use cardiac output monitoring regardless of study group allocation; this is considered ‘clinician refusal’ Patients will be managed by the care team according to usual practice. Patients should not be randomised if the clinician intends to use cardiac output monitoring regardless of study group allocation; this is considered ‘clinician refusal’ and is a specific exclusion criteria. However, clinical staff are free to request cardiac output monitoring if this is required to inform the treatment of a patient who becomes critically ill (e.g. because of severe haemorrhage) during the trial intervention period. In this situation a protocol deviation form will be completed.
25
Non-Compliance Participant in the intervention group did NOT receive cardiac output monitoring Participant in the control group DID receive cardiac output monitoring FLO-ELA algorithm not followed in intervention group Any suspected protocol deviations should be reported to the local research team for review. Note that the use of ANY FORM of cardiac output monitoring (including anaesthetic modules providing just PPV/SPV values) count as non-compliance if used in the control group. Record in the CRF supplementary form – protocol deviations/ Non compliance.
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.